TLCR was a 2005 spinoff from Bayer. It tried to be acquired by CSL (the world’s largest plasma-protein company), but this was blocked by the FTC (#msg-38107926). Instead, TLCR IPO’d in 2009, but it was always crystal clear that the goal was to be acquired.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”